Clinical trials: Adenovirus Disease
HIV Infections
"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection
This study will determine the safety and side effects of two experimental HIV vaccines given in a "prime-boost" schedule. It will also monitor participants for the social impact of being in an HIV vaccine study (e.g., problems…
- Trial name
- NCT00109629
- Testing
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adenoviral Conjunctivitis
An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis
The purpose of this study is to evaluate the safety and efficacy of AL-46383A Ophthalmic Solution for the treatment of adenoviral conjunctivitis.
- Trial name
- NCT00901693
- Testing
- AL-46383A Ophthalmic Solution, AL-46383A Ophthalmic Solution Vehicle
- Volunteers
- 452 people
- Sponsor
- Alcon Research
Colon Cancer
Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer
The purpose of this study is to determine the safety, tolerability and ability to stimulate hGCC-specific antibody and killer T cell immune responses of an Ad5-hGCC-PADRE vaccine in stage I and stage II Caucasian and African…
- Trial name
- NCT01972737
- Testing
- Ad5-hGCC-PADRE vaccine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
COVID-19
A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.
The study is a single-center, randomized and double-blinded trial to evaluate the immunobridging between different manufacture scales, lot-to-lot consistency of the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5…
- Trial name
- NCT04916886
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
- Where
- China
- Volunteers
- 2,021 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Hypothermia, Primary Intracerebral Hemorrhage
Pilot Study of Hypothermia for Intracerebral Hemorrhage in Croatia
In this pilot study the researchers will investigate efficacy of hypothermia in the early stage of treatment patients with primary intracerebral hemorrhage.
- Conditions
- Hypothermia, Primary Intracerebral Hemorrhage, Signs and Symptoms
- Trial name
- NCT01221142
- Testing
- Cincinnati Sub-Zero," Blanketrol III"
- Where
- Croatia
- Volunteers
- 20 people
- Sponsor
- University of Rijeka
Metastatic Colorectal Cancer, Colorectal Neoplasms
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
Background: Gastrointestinal cancer is one of the most common cancers worldwide. Researchers think an unmet need exists to understand and improve treatment options.
- Conditions
- Metastatic Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Cancer With Hepatic Metastases
- Trial name
- NCT04166383
- Testing
- Vascular Biogenics (VB)-111, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Ebola Viral Disease
A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of 3 vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens.
- Trial name
- NCT02416453
- Testing
- MVA-BN-Filo, Ad26.ZEBOV
- Where
- 11 sites in France, United Kingdom
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Respiratory Syncytial Virus Infections
RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.
In this study we are testing a new vaccine against Respiratory Syncytial Virus (RSV). This virus can cause respiratory infections such as bronchiolitis and pneumonia.
- Trial name
- NCT01805921
- Testing
- PanAd3-RSV given intra-nasally (high dose), MVA-RSV given by intra-muscular injection (high dose), PanAd3-RSV given by intra-muscular injection (high dose)
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- ReiThera Srl
Corneal Disease
Corneal Densitometry Changes With Adenoviral SEI
Adenoviral Sub epithelial infiltrates (SEI) affect ocular function.They lead to reduced vision, photophobia, glare, halos, and foreign body sensation.
- Trial name
- NCT04267991
- Testing
- Tacrolimus ointment, phototherapeutic keratectomy
- Where
- United Arab Emirates
- Volunteers
- 63 people
- Sponsor
- Benha University
Adenovirus Infection
Clinical Grade Adenovirus Specific T Cells for Immunotherapy After Allogeneic Stem Cell Transplantation (CTL-ADV)
Fourteen patients will be included for infusion of adenovirus-specific T-cells generated by a clinical grade IFN-γ based immunomagnetic isolation from a leukapheresis from their original donor or a haploidentical donor, in case…
- Trial name
- CTL-ADV (NCT02851576)
- Testing
- Infusion of ADV specific T cells
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Central Hospital, Nancy, France
COVID-19
Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine
This is a multicenter, open-label, partially radomized, parallel-controlled clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolised adenovirus type-5 vector-based…
- Trial name
- NCT05204589
- Testing
- Aerosolized Ad5-nCoV, Inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 10,285 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Ebola Virus Disease
A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization
Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain…
- Trial name
- NCT02533791
- Testing
- 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV), 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Respiratory Viral Illnesses: Influenza A/B, RSV, Adenovirus
Residual Sample Collection for Respiratory Viral Panel
Collect de-identified, residual samples to support a clinical trial. Samples may be prospectively or retrospectively collected. Overall Study Objective Obtain clinical performance data to characterize clinical performance of the…
- Trial name
- NCT02049918
- Where
- United States
- Volunteers
- 1,487 people
- Sponsor
- GenMark Diagnostics
Adenovirus
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
This is a randomized, controlled, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetic (PK), and adenovirus (AdV) antiviral activity of multiple ascending doses of IV brincidofovir (BCV).
- Trial name
- NCT03532035
- Testing
- Brincidofovir, Standard of Care
- Where
- 8 sites in United States, Italy and 1 more
- Sponsor
- Jazz Pharmaceuticals
Esophageal Neoplasms
Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma
This study is a randomized, double-blinded assessment of biologic efficacy of AdcuCD40L. The individuals enrolled in this study will be individuals with biopsy proven resectable esophageal carcinoma.
- Trial name
- cd40 (NCT00504322)
- Testing
- AdcuCD40L
- Sponsor
- Weill Medical College of Cornell University
Hepatocellular Carcinoma
HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
Hepatic artery infusion chemotherapy (HAIC) is effective and safe for hepatocellular carcinoma (HCC). Recombinant Human Type-5 Adenovirus (H101) is safe for HCC.
- Trial name
- NCT03780049
- Testing
- HAIC of FOLFOX, H101
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Sun Yat-sen University
Colorectal Carcinoma, Colorectal Neoplasm
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome.
- Conditions
- Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
- Trial name
- NCT05419011
- Testing
- Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 186 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer
H101 is an E1B55KD deleted oncolytic adenovirus, which is the first and only adenovirus to be approved by China State Food and Drug Administration in 2005 for treating head and neck cancer.
- Trial name
- NCT05564897
- Testing
- H101, Camrelizumab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Lung Cancer
Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Inserting the gene for p53 into a person's cancer cells may improve the body's ability to fight cancer. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004225
- Testing
- Ad5CMV-p53 gene, radiation therapy
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Breast Neoplasms
Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2
We, the researchers at Hamilton Health Sciences, have developed a novel approach to cancer therapy using transfected dendritic cells (DCs) to generate enhanced immunity to defined tumor antigens.
- Trial name
- NCT00197522
- Testing
- CD34+ derived DCs
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Hamilton Health Sciences Corporation